Tyra Biosciences Stock Performance
| TYRA Stock | USD 10.69 0.25 2.29% |
The entity has a beta of 1.0, which indicates possible diversification benefits within a given portfolio. Tyra Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Tyra Biosciences is expected to follow. At this point, Tyra Biosciences has a negative expected return of -0.42%. Please make sure to validate Tyra Biosciences' kurtosis, as well as the relationship between the day median price and relative strength index , to decide if Tyra Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tyra Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.29) | Five Day Return (1.57) | Year To Date Return (25.92) | Ten Year Return (58.88) | All Time Return (58.88) |
1 | Disposition of 835 shares by Kjellson Nina S of Tyra Biosciences at 16.287 subject to Rule 16b-3 | 01/16/2025 |
2 | Disposition of 93 shares by Kjellson Nina S of Tyra Biosciences at 16.3626 subject to Rule 16b-3 | 01/21/2025 |
3 | Tyra Biosciences, Inc. Director Nina S. Kjellson Sells 7,779 Shares | 01/22/2025 |
4 | Disposition of 4825 shares by Kjellson Nina S of Tyra Biosciences at 16.2624 subject to Rule 16b-3 | 01/23/2025 |
5 | Insider Selling Tyra Biosciences, Inc. Director Sells 4,825 Shares of Stock - MarketBeat | 01/27/2025 |
6 | Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors | 01/29/2025 |
7 | Disposition of 3511 shares by Kjellson Nina S of Tyra Biosciences at 13.7611 subject to Rule 16b-3 | 02/05/2025 |
8 | Tyra Biosciences to Present at Upcoming Investor Conferences - Quantisnow | 02/11/2025 |
9 | Tyra Biosciences Stock Price Up 6.6 percent - Heres What Happened - MarketBeat | 02/18/2025 |
10 | BlueNord Update on Tyra Redevelopment Project and Tyra Completion Test | 02/28/2025 |
11 | Disposition of 73093 shares by Daniel Bensen of Tyra Biosciences at 16.3066 subject to Rule 16b-3 | 03/03/2025 |
12 | Disposition of 1890 shares by Kjellson Nina S of Tyra Biosciences at 13.7611 subject to Rule 16b-3 | 03/07/2025 |
13 | Rhumbline Advisers Grows Stake in Tyra Biosciences, Inc. - Defense World | 03/10/2025 |
14 | Disposition of 4900 shares by Todd Harris of Tyra Biosciences at 25.2155 subject to Rule 16b-3 | 03/13/2025 |
15 | Why Precision BioSciences Shares Are Trading Higher By Over 10 Here Are 20 Stocks Moving Premarket - Benzinga | 03/17/2025 |
| Begin Period Cash Flow | 252.2 M |
Tyra |
Tyra Biosciences Relative Risk vs. Return Landscape
If you would invest 1,425 in Tyra Biosciences on December 21, 2024 and sell it today you would lose (356.00) from holding Tyra Biosciences or give up 24.98% of portfolio value over 90 days. Tyra Biosciences is currently does not generate positive expected returns and assumes 3.4818% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Tyra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tyra Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tyra Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tyra Biosciences, and traders can use it to determine the average amount a Tyra Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1203
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TYRA |
Estimated Market Risk
| 3.48 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tyra Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tyra Biosciences by adding Tyra Biosciences to a well-diversified portfolio.
Tyra Biosciences Fundamentals Growth
Tyra Stock prices reflect investors' perceptions of the future prospects and financial health of Tyra Biosciences, and Tyra Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tyra Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 210.92 M | ||||
| Shares Outstanding | 50.6 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 1.56 X | ||||
| EBITDA | (79.59 M) | ||||
| Net Income | (69.13 M) | ||||
| Cash And Equivalents | 275.11 M | ||||
| Cash Per Share | 6.61 X | ||||
| Total Debt | 6.5 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 50.83 X | ||||
| Book Value Per Share | 6.85 X | ||||
| Cash Flow From Operations | (50.14 M) | ||||
| Earnings Per Share | (1.61) X | ||||
| Market Capitalization | 553.6 M | ||||
| Total Asset | 225.86 M | ||||
| Retained Earnings | (164.83 M) | ||||
| Working Capital | 196.34 M | ||||
About Tyra Biosciences Performance
By analyzing Tyra Biosciences' fundamental ratios, stakeholders can gain valuable insights into Tyra Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Tyra Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tyra Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Tyra Biosciences performance evaluation
Checking the ongoing alerts about Tyra Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tyra Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tyra Biosciences generated a negative expected return over the last 90 days | |
| Tyra Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (69.13 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tyra Biosciences currently holds about 275.11 M in cash with (50.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.61. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Why Precision BioSciences Shares Are Trading Higher By Over 10 Here Are 20 Stocks Moving Premarket - Benzinga |
- Analyzing Tyra Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tyra Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Tyra Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tyra Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tyra Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tyra Biosciences' stock. These opinions can provide insight into Tyra Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |